Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Macular Edema - Overview
Macular Edema - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Macular Edema - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macular Edema - Companies Involved in Therapeutics Development
Anew Oncology Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Coherus BioSciences Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
OMEICOS Therapeutics GmbH
PharmAbcine Inc
Polus Inc
Profarma
Sustained no Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Xbrane Biopharma AB
Macular Edema - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Featured News & Press Releases
Apr 28, 2020: Clearside Biomedical revises NDA resubmission timeline and XIPERE commercial partnership with Bausch Health
Jan 28, 2020: Bausch Health and Clearside Biomedical announce publication of PIVOTAL phase 3 data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology
Aug 22, 2019: Clearside Biomedical provides new drug application update for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)
Jul 31, 2019: Clearside Biomedical announces multiple oral presentations delivered at the American Society of Retil Specialists (ASRS) Annual Meeting
May 01, 2019: Clearside Biomedical presents on Triamcinolone at the American Uveitis Society Spring Meeting 2019
Apr 18, 2019: Clearside Biomedical announces presentations on its Suprachoroidal Space injection platform with Triamcinolone Acetonide at upcoming medical meetings
Feb 20, 2019: Clearside Biomedical receives notification of FDA acceptance of NDA filing for XIPERE (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection with PDUFA Date Set for October 19, 2019
Jan 20, 2019: Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE Exhibits Durability Following Second Dose
Dec 19, 2018: Clearside Biomedical submits New Drug Application for XIPERE for the treatment of Macular Edema associated with Uveitis
Oct 29, 2018: Presentation of additiol alyses of Clearsides PEACHTREE clinical trial data further supports potential of XIPERE in treating uveitic macular edema
Oct 22, 2018: CLEARSIDE, XIPERE and PEACHTREE to be front and center at AAO 2018
Sep 18, 2018: Positive PEACHTREE Data to be Highlighted at EURETI 2018
Sep 13, 2018: Data from Clearside Biomedical’s pivotal phase 3 PEACHTREE clinical trial in macular edema associated with non-infectious uveitis to be presented at the Reti Society 51st Annual Scientific Meeting
Sep 12, 2018: Single suprachoroidal steroid injection boosts visual acuity in patients with macular edema
Jul 16, 2018: Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Reti Specialists Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Macular Edema, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Macular Edema, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Macular Edema - Pipeline by Anew Oncology Inc, H1 2020
Macular Edema - Pipeline by AsclepiX Therapeutics Inc, H1 2020
Macular Edema - Pipeline by Celon Pharma SA, H1 2020
Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2020
Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2020
Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Macular Edema - Pipeline by Formycon AG, H1 2020
Macular Edema - Pipeline by Lupin Ltd, H1 2020
Macular Edema - Pipeline by Luye Pharma Group Ltd, H1 2020
Macular Edema - Pipeline by Mabion SA, H1 2020
Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H1 2020
Macular Edema - Pipeline by PharmAbcine Inc, H1 2020
Macular Edema - Pipeline by Polus Inc, H1 2020
Macular Edema - Pipeline by Profarma, H1 2020
Macular Edema - Pipeline by Sustained Nano Systems LLC, H1 2020
Macular Edema - Pipeline by Taiwan Liposome Co Ltd, H1 2020
Macular Edema - Pipeline by Targeted Therapy Technologies LLC, H1 2020
Macular Edema - Pipeline by Tarsius Pharma Ltd, H1 2020
Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2020
Macular Edema - Dormant Projects, H1 2020
Macular Edema - Discontinued Products, H1 2020